Thursday, June 8, 2023
Clinical Advances in
Read Overview
Supported by an educational grant from Regeneron Pharmaceuticals, Inc.
Steering Committee Chair
Professor
Deputy Chair, Department of Melanoma Medical Oncology
Co-Director, MD Anderson Brain Metastasis Clinic
Melanoma Medical Oncology, Investigational Cancer Therapeutics
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Professor of Medicine, NYU Grossman School of Medicine
Associate Director for Clinical Research
Director, Melanoma and Cutaneous Medical Oncology
Laura and Isaac Perlmutter Cancer Center at NYU
New York, New York
Professor and Chairman
Department of Melanoma Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Associate Professor of Oncology
Johns Hopkins University
Baltimore, Maryland
Nurse Practitioner
Center for Melanoma
Massachusetts General Hospital
Boston, Massachusetts
Steering Committee Chair
Has disclosed the following relevant financial relationships:
Consultant or advisor for: Boxer Capital; Bristol Myers Squibb; Eisai; Genentech; Iovance; Jazz Pharaceuticals; Karyopharm; Medicenna; Merck; Novartis
Research funding from: Bristol Myers Squibb; Dragonfly Therapeutics; Eisai; EMD Serono; Genentech; GlaxoSmithKline; Merck; Novartis; RAPT Therapeutics
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: Merck
Speaker or member of speakers bureau for: Bristol Myers Squibb; Eisai; Novartis; Regeneron; Seagen, Inc.
Research funding from: Bristol Myers Squibb; Incyte; Kinnat; Merck; Novartis
Stock options from: Pfizer
Owns stock (publicly traded) in: Pfizer
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: ABM Therapeutics; Apexigen; Array; Bristol Myers Squibb; Eisai; Iovance; Novartis; Pfizer; Roche/Genentech; Vaccinex
Research funding from: ABM Therapeutics; LEAD Pharma
Contracted researcher for: Pfizer
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb; CareDx; Eisai; Genentech; Immunocore; Instil Bio; MacroGenics; Merck; Natera; Nektar Therapeutics; Odonate Therapeutics; OncoSec; Pfizer; Rain Therapeutics; Regeneron; Sanofi
Research funding from: Bristol Myers Squibb; Merck; Regeneron; Sanofi
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb; Eisai; ImmunoCore; Merck
